Skip to main content
SRTA logo

SRTA · Strata Critical Medical, Inc. · Financials

Track SRTA — free
$5.56 +0.30 (+5.70%) At close · Nov 6 Play latest call Q3 2026 earnings call transcript
Market Cap
$491.43M
Shares
88.47M
Volume · Nov 6 1.35M Avg daily vol (3M) 944.97K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$197.14M +34.3%
FY2025 Revenue FY2021–FY2025
Net Income
$41.35M +251.4%
FY2025 Net Income FY2019–FY2025
Gross Margin
20.86% +0.7pp
FY2025 Gross Margin FY2021–FY2025
Operating Margin
-11.34% +4pp
FY2025 Operating Margin FY2021–FY2025
Diluted EPS
$0.50 +242.9%
FY2025 Diluted EPS FY2021–FY2025
Operating Cash Flow
-$48.91M -1841.8%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
$285M – $295M $280.76M $197.14MG $146.82MG $225.18M $146.12M $50.53M — —
— — — $7.21M $8.44M $3.43M $460K — —
— $220.19M $156.02M $117.23M $183.06M $123.85M $40.01M — —
— $60.56M $41.13M $29.59M $42.12Md $22.28Md $10.52Md — —
— — 20.86% 20.15% 18.71%d 15.24%d 20.82%d — —
— — — $3.18M $4.63M $5.55M $1.68M — —
— — — $7.95M $10.44M $7.75M $2.79M — —
— — — $81.71M $95.17M $62.51M $30.14M — —
— $64.08M $60.88M $50.86M — — — — —
— $15.1M $2.6M $1.26M $6.04M $4.9M $243K — —
— $21.9M $8.19M $5.96M $7.11M $5.73M $596K — —
— $79.18M $63.48M $52.11M -$33.23M -$36.57M -$24.94M $678.49K —
— — — $282.62M $293.3M $199.65M $74.62M — —
— -$18.62M -$22.35M -$22.53M -$68.12M -$53.53M -$24.09M -$678.49K —
— — -11.34% -15.34% -30.25% -36.63% -47.68% — —
— $3.28M -$14.17M -$16.56M -$61.01M -$47.8M -$23.5M — —
— -$2.5M $2.29M $6.36M $10.58M $25.5M -$19.6M — —
— -$21.12M -$20.07M -$16.16M -$57.54M -$28.03M -$43.7M -$20.31M —
— $0 $0 $0 -$1.47M -$772K -$3.64M $210.47K $208.61K
— -$24.81M $41.35M -$27.31M -$56.08M -$27.26M -$40.05M -$20.52M $2.33M
— — 20.97% -18.6% -24.9% -18.66% -79.27% — —
— — — — — -$27.26M — — —
— -$24.81M $39.59M -$29.52M -$54.4M -$24.08M -$40.35M — —
USD/shares — -$0.29 $0.50 -$0.35 -$0.76 -$0.38 -$0.93 — —
USD/shares — -$0.29 $0.50 -$0.35 -$0.76 -$0.38 -$0.93 — —
shares — — 82.09M 77.5M 73.52M 71.24M 42.88M 9.69M 8.03M
shares — — 82.09M 77.5M 73.52M 71.24M 42.88M 9.69M 8.03M
d Gross profit for periods the company did not report it, or tagged its operating income as gross profit, is Revenue − Cost of Revenue. Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $244K in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-09-30 USD 858,000 10-Q filed 2026-11-03
Noncurrent operating lease liabilities 2026-09-30 USD 2,765,000 10-Q filed 2026-11-03
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
1.63×
Peer median 1.31×
EV/EBIT
—
Peer median 18.69×
P/E (TTM)
—
Peer median 20.68×
Price/Sales (TTM)
1.75×
Peer median 1.06×
Price/Book
1.78×
Peer median 3.04×
EV/Adj. EBITDA (FY2025)
32.47×
Peer median 12.22×

Peer medians compare against the 27 similar-size Medical Care Facilities companies (of 57 listed).

EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.

Valuation over time computed as of each quarter's filing date

EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021
Logistics $176,793,000 $146,817,000 — — —
Clinical $20,348,000 $0 — — —
Medical Segment — — $126,604,000 $71,779,000 $6,401,000
Passenger Segment — — $98,576,000 $74,341,000 $44,125,000

By Geography (USD)

Component FY2024 FY2023 FY2022 FY2021
United States $218,747,000 $190,744,000 $133,298,000 $50,526,000
Non Us $29,946,000 $34,436,000 $12,822,000 $0

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Other Clinical $11,384,000 $0 — — — — —
Transplant Clinical $8,964,000 $0 — — — — —
Jet and Other — $29,673,000 $27,876,000 $29,355,000 — — —
Medi Mobility Organ Transport And Jet — $146,817,000 $126,604,000 $71,779,000 $26,346,000 $13,476,000 $5,071,000
Other — — — — $1,927,000 $492,000 $85,000
Short Distance — $72,203,000 $70,700,000 $44,986,000 $22,253,000 $9,466,000 $26,040,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component FY2023 FY2022 FY2021
Medical Segment -$1,388,000 -$2,930,000 $446,000
Passenger Segment -$33,503,000 -$14,029,000 $404,000

Operating Margin by Segment (%)

Component FY2023 FY2022 FY2021
Medical Segment -1.1% -4.1% 7%
Passenger Segment -34% -18.9% 0.9%
Key facts CIK 1779128 CUSIP 092667104 13F (30d) 70 filings 55 filers Visit website Investor relations